Similarly, in TCGA database, AML patients with co-low expression of TXNIP, NLRP3 and CASP1 or TXNIP, NLRP3 and IL1B had longer RMST (3-year RMST: TXNIPlowNLRP3lowCASP1low vs. TXNIPhighNLRP3highCASP1high vs. TXNIPhigh or NLRP3high or CASP1high, 787 vs. 558 vs. 476 days; 3-year RMST: TXNIPlowNLRP3lowIL1Blow vs. TXNIPhighNLRP3highIL1Bhigh vs. TXNIPhigh or NLRP3high or IL1Bhigh, 736 vs. 447 vs. 550 days, Figure 3B and 3C). This evidence concerns the gene TXNIP and acute myeloid leukemia.